HK1109350A1 - Solid forms of a chemokine receptor antagonist and methods of use thereof - Google Patents

Solid forms of a chemokine receptor antagonist and methods of use thereof

Info

Publication number
HK1109350A1
HK1109350A1 HK08103587.5A HK08103587A HK1109350A1 HK 1109350 A1 HK1109350 A1 HK 1109350A1 HK 08103587 A HK08103587 A HK 08103587A HK 1109350 A1 HK1109350 A1 HK 1109350A1
Authority
HK
Hong Kong
Prior art keywords
citrate salt
methods
crystalline
discussed
receptor antagonist
Prior art date
Application number
HK08103587.5A
Other languages
English (en)
Inventor
Carole Neves
Aurelia Chevalier
Pascal Billot
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of HK1109350A1 publication Critical patent/HK1109350A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK08103587.5A 2004-12-17 2008-04-01 Solid forms of a chemokine receptor antagonist and methods of use thereof HK1109350A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63721304P 2004-12-17 2004-12-17
PCT/US2005/045915 WO2006066200A2 (en) 2004-12-17 2005-12-19 Solid forms of a chemokine receptor antagonist and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1109350A1 true HK1109350A1 (en) 2008-06-06

Family

ID=36588631

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08103587.5A HK1109350A1 (en) 2004-12-17 2008-04-01 Solid forms of a chemokine receptor antagonist and methods of use thereof

Country Status (10)

Country Link
US (2) US7960549B2 (es)
EP (1) EP1841429B1 (es)
JP (3) JP5308030B2 (es)
CN (1) CN101119725B (es)
AT (1) ATE553761T1 (es)
AU (1) AU2005316340B2 (es)
CA (1) CA2590157C (es)
ES (1) ES2386029T3 (es)
HK (1) HK1109350A1 (es)
WO (1) WO2006066200A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220389024A1 (en) * 2019-11-29 2022-12-08 Sunshine Lake Pharma Co., Ltd. Crystalline form of nitrogen-containing tricyclic compound and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2319077A1 (en) 1998-01-21 1999-07-29 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
EP1047675A1 (en) 1998-01-21 2000-11-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EA008060B1 (ru) * 1998-09-04 2007-02-27 Милленниум Фармасьютикалз, Инк. Антагонисты хемокинного рецептора и способы их применения
US20020169155A1 (en) * 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
JP2002524461A (ja) 1998-09-04 2002-08-06 ミレニアム・ファーマシューティカルズ・インコーポレイテッド ケモカイン受容体アンタゴニストおよびその使用方法
AU6503900A (en) 1999-07-28 2001-02-19 Kyowa Hakko Kogyo Co. Ltd. Chemokine receptor antagonists and methods of use therefor
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
EP1841429B1 (en) 2012-04-18
ES2386029T3 (es) 2012-08-07
CA2590157A1 (en) 2006-06-22
CN101119725A (zh) 2008-02-06
US20070010545A1 (en) 2007-01-11
WO2006066200A3 (en) 2007-01-25
JP2015057445A (ja) 2015-03-26
WO2006066200A2 (en) 2006-06-22
AU2005316340A1 (en) 2006-06-22
CA2590157C (en) 2013-11-05
AU2005316340B2 (en) 2012-01-19
US20120065223A1 (en) 2012-03-15
EP1841429A2 (en) 2007-10-10
JP2012211197A (ja) 2012-11-01
US8481737B2 (en) 2013-07-09
ATE553761T1 (de) 2012-05-15
JP2008524253A (ja) 2008-07-10
US7960549B2 (en) 2011-06-14
CN101119725B (zh) 2013-04-17
JP5308030B2 (ja) 2013-10-09

Similar Documents

Publication Publication Date Title
GEP20063905B (en) Crystalline monohydrate, method for producing the same and the use thereof in the production of a medicament
WO2005016261A3 (en) Aripiprazole and haloperidol pamoate salts
WO2005089753A3 (en) Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders
WO2003084539A3 (en) New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
IL175259A0 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2005089486A3 (en) Methods for treating alcoholism
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP2272850A3 (en) Process for purifying staurosporine
WO2006047392A3 (en) Nicotinic-opioid synergy for analgesia
WO2008026156A3 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
WO2008123582A1 (ja) テトラヒドロイソキノリン化合物
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
WO2005089449A3 (en) Methods for treating alcoholism
WO2004103283A3 (en) Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
WO2005118613A3 (de) Antibakterielle amid-makrozyklen
WO2004082584A3 (en) 5ht2c receptor antagonists in the treatment of schizophrenia
HK1109350A1 (en) Solid forms of a chemokine receptor antagonist and methods of use thereof
WO2006034106A3 (en) Baff variants and methods therof
WO2008032222A3 (en) Treatment of vertigo with acetyl-l-leucine
WO2005094798A3 (en) Pharmaceutical compositions based on anticholinergics and ccr2 receptor antagonists
WO2008019276A3 (en) Solid forms of (3'-chlorobiphenyl-4-yl)(1-(pyrimidin-2-yl)piperidin-4-yl)methanone and methods of their use
IL173918A0 (en) Substituted thienoimidazoles, method for production and use thereof as medicament or diagnostic and medicaments comprising the same
WO2005063757A3 (en) Novel crystalline forms of temozolomide
MY146601A (en) Chemokine receptor antagonists and methods of use therefor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151219